| Literature DB >> 26966009 |
Oscar Solís1,2, Patricia García-Sanz1,2, Antonio S Herranz3, María-José Asensio3, Rosario Moratalla4,5.
Abstract
Perturbations in the cerebral levels of various amino acids are associated with neurological disorders, and previous studies have suggested that such alterations have a role in the motor and non-motor symptoms of Parkinson's disease. However, the direct effects of chronic L-DOPA treatment, that produces dyskinesia, on neural tissue amino acid concentrations have not been explored in detail. To evaluate whether striatal amino acid concentrations are altered in peak dose dyskinesia, 6-hydroxydopamine (6-OHDA)-lesioned hemiparkinsonian mice were treated chronically with L-DOPA and tissue amino acid concentrations were assessed by HPLC analysis. These experiments revealed that neither 6-OHDA nor L-DOPA treatment are able to alter glutamate in the striatum. However, glutamine increases after 6-OHDA and returns back to normal levels with L-DOPA treatment, suggesting increased striatal glutamatergic transmission with lack of dopamine. In addition, glycine and taurine levels are increased following dopamine denervation and restored to normal levels by L-DOPA. Interestingly, dyskinetic animals showed increased levels of GABA and tyrosine, while aspartate striatal tissue levels are not altered. Overall, our results indicate that chronic L-DOPA treatment, besides normalizing the altered levels of some amino acids after 6-OHDA, robustly increases striatal GABA and tyrosine levels which may in turn contribute to the development of L-DOPA-induced dyskinesia.Entities:
Keywords: Abnormal involuntary movements; GABA; Glutamate; Glutamine; Glycine; Parkinson’s disease; Taurine; Tyrosine
Mesh:
Substances:
Year: 2016 PMID: 26966009 DOI: 10.1007/s12640-016-9612-x
Source DB: PubMed Journal: Neurotox Res ISSN: 1029-8428 Impact factor: 3.911